Allolithocholic acid

Name: Allolithocholic acid
Brand: MedChemExpress
SKU: HY-143712
Rating: 4.5 (1 reviews)

Cat. No.: HY-143712 Purity: 99.69%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC₅₀ = 2.7 μM) and RORγt inverse agonist (IC₅₀ = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.

For research use only. We do not sell to patients.

Allolithocholic acid Chemical Structure

CAS No. : 2276-94-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Allolithocholic acid:

Lithocholic acid In-stock
Allolithocholic Acid-d₄ Get quote
Allolithocholic acid (Standard) Get quote

1 Publications Citing Use of MCE Allolithocholic acid

•Nature. 2025 Jul;643(8070):192-200.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ROR Isoform Specific Products:

View All Isoforms

RORγ RORα RORβ

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

RORγt

3.4 μM (IC₅₀)

In Vitro

Allolithocholic acid activates human GPBAR1 in HEK-293T cells with an EC₅₀ of 2.7 μM^[1].
Allolithocholic acid inhibits human RORγt in HEK-293T cells with an IC₅₀ of 3.4 μM^[1].
Allolithocholic acid (1 μM; 24 h) shifts polarized human M1 macrophages toward an M2-like phenotype by reducing pro-inflammatory marker expression and increasing anti-inflammatory marker expression^[1].
Allolithocholic acid (1 μM; 72 h) inhibits Th17 polarization and promotes Treg polarization of human CD4⁺ T lymphocytes^[1].
Allolithocholic acid (1-10 μM; 24 h) dose-dependently reduces pro-fibrotic gene expression in TGFβ-activated primary hepatic stellate cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:	Macrophages
Concentration:	1 μM
Incubation Time:	24 h
Result:	Reduced expression of CD38 and TNFα and ncreased the expression of CD206 and L-10.

In Vivo

Allolithocholic acid (10 mg/kg; i.g.; daily; 7 weeks) significantly attenuates liver steatosis, fibrosis, insulin resistance, and inflammation in a mouse model of metabolic dysfunction-associated steatohepatitis, while restoring bile acid homeostasis, adipose tissue function, and gut microbiota balance^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J (male, metabolic dysfunction-associated steatohepatitis model induced by high fat/high fructose diet + 200 µl/kg carbon tetrachloride i.p. every 2 weeks for 8 weeks)^[1]
Dosage:	10 mg/kg
Administration:	I.g.,; daily; 7 weeks
Result:	Reduced oral glucose tolerance test area under the curve compared to untreated disease model mice. Reduced plasma aspartate transferase, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels; did not significantly alter triglyceride levels. Lowered systolic blood pressure and white blood cell counts. Reduced liver steatosis (lowered NAFLD Activity Score and hepatic cholesterol content) and liver fibrosis (reduced collagen deposition area percentage). Reversed disease-induced shifts in bile acid pool composition in liver, plasma, and stool, including reducing levels of α/β-muricholic acid and their taurine conjugates, and decreasing primary/secondary bile acid ratio. Downregulated 2117 liver genes (including pro-inflammatory chemokines Ccl2, Ccl3, Ccl7, Cxcl12; interferon signaling genes Stat2, Irf9, Jak3; NF-κB signaling genes Irak2, Traf5, Ikbkb; and metabolic genes AdipoQ, Pnpla3, Lpl, Srebf1) compared to untreated disease model mice. Decreased adipocyte diameter, increased adipocyte number; reduced adipose tissue mRNA expression of TNFα, IL-6, adiponectin-1, resistin, and leptin. Reduced the Firmicutes/Bacteroidetes ratio by increasing Bacteroidetes abundance, and increased Bifidobacterium levels.

Molecular Weight

376.57

Formula

C₂₄H₄₀O₃

CAS No.

2276-94-0

Appearance

Solid

Color

White to light yellow

SMILES

C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(O)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@@](C[C@@H](CC4)O)([H])CC3)C

Structure Classification

Steroids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (66.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6555 mL	13.2777 mL	26.5555 mL
5 mM	0.5311 mL	2.6555 mL	5.3111 mL
10 mM	0.2656 mL	1.3278 mL	2.6555 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.32 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.32 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.69%

Select Batch:

Data Sheet (279 KB) SDS (394 KB)

COA (248 KB) RP-HPLC (247 KB)

Handling Instructions (2659 KB)

References

[1]. Marchianò S, et al. Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis. Biochem Pharmacol. 2025;236:116883. [Content Brief]

[2]. Lee JW, et al. Formation of secondary allo-bile acids by novel enzymes from gut Firmicutes. Gut Microbes. 2022;14(1):2132903. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6555 mL	13.2777 mL	26.5555 mL	66.3887 mL
	5 mM	0.5311 mL	2.6555 mL	5.3111 mL	13.2777 mL
	10 mM	0.2656 mL	1.3278 mL	2.6555 mL	6.6389 mL
	15 mM	0.1770 mL	0.8852 mL	1.7704 mL	4.4259 mL
	20 mM	0.1328 mL	0.6639 mL	1.3278 mL	3.3194 mL
	25 mM	0.1062 mL	0.5311 mL	1.0622 mL	2.6555 mL
	30 mM	0.0885 mL	0.4426 mL	0.8852 mL	2.2130 mL
	40 mM	0.0664 mL	0.3319 mL	0.6639 mL	1.6597 mL
	50 mM	0.0531 mL	0.2656 mL	0.5311 mL	1.3278 mL
	60 mM	0.0443 mL	0.2213 mL	0.4426 mL	1.1065 mL